Golden State Equity Partners’s Merck MRK Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$4.13M Buy
34,368
+9,907
+41% +$1.14M 0.31% 66
2025
Q4
$2.57M Sell
24,461
-1,105
-4% -$104K 0.42% 44
2025
Q3
$2.15M Sell
25,566
-1,402
-5% -$115K 0.36% 57
2025
Q2
$2.13M Sell
26,968
-13,135
-33% -$1.04M 0.4% 54
2025
Q1
$3.6M Buy
40,103
+121
+0.3% +$11.3K 0.71% 25
2024
Q4
$3.98M Buy
39,982
+39,242
+5,303% +$4.05M 0.76% 20
2024
Q3
$84K Sell
740
-27,597
-97% -$3.28M 0.04% 304
2024
Q2
$3.51M Buy
+28,337
New +$3.65M 0.73% 21
2023
Q4
$3.14M Sell
28,831
-68
-0.2% -$7.06K 0.76% 26
2023
Q3
$2.98M Sell
28,899
-134
-0.5% -$14.4K 0.83% 25
2023
Q2
$3.35M Buy
29,033
+6,538
+29% +$742K 0.94% 20
2023
Q1
$2.39M Buy
+22,495
New +$2.43M 1.3% 17
2022
Q1
$1.82M Sell
22,236
-7,660
-26% -$604K 0.92% 30
2021
Q4
$2.29M Buy
29,896
+10,876
+57% +$866K 1.16% 27
2021
Q3
$1.43M Sell
19,020
-1,334
-7% -$101K 0.58% 39
2021
Q2
$1.58M Sell
20,354
-2,608
-11% -$194K 0.61% 36
2021
Q1
$1.69M Buy
22,962
+3,169
+16% +$234K 0.96% 29
2020
Q4
$1.54M Buy
+19,793
New +$1.51M 1.06% 25

Other funds holding MRK

Golden State Equity Partners's MRK Position: Q1 2026 in Review

Golden State Equity Partners increased its Merck (MRK) stake by 41% in Q1 2026, buying an estimated $1.14M and bringing the position to 34,368 shares worth $4.13M. The position accounts for 0.31% of the portfolio, ranked #66.

Golden State Equity Partners first reported a position in MRK in Q4 2020 and has held it in 18 quarters since. 3,777 funds tracked by Wall St. Rank hold MRK as of Q1 2026.

  • Golden State Equity Partners held 34,368 shares of Merck worth $4.13M as of Q1 2026.
  • Golden State Equity Partners bought 9,907 Merck shares in Q1 2026, an estimated $1.14M.
  • Merck made up 0.31% of Golden State Equity Partners's portfolio in Q1 2026, its #66 holding.
  • Golden State Equity Partners first reported a position in Merck in Q4 2020 and has held it in 18 quarters since.
  • 3,777 funds tracked by Wall St. Rank held Merck as of Q1 2026.

Based on Golden State Equity Partners's 13F filing for Q1 2026, filed 28 Apr 2026.